<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468244</url>
  </required_header>
  <id_info>
    <org_study_id>CHO-01002</org_study_id>
    <nct_id>NCT03468244</nct_id>
  </id_info>
  <brief_title>Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms</brief_title>
  <official_title>Clinical Study of Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stemirna Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single arm, open-label pilot study is designed to determine the safety, tolerability and&#xD;
      effectiveness of personalized mRNA tumor vaccine encoding neoantigen in Patients with&#xD;
      advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma and&#xD;
      colorectal adenocarcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dr. Bin Wang developed the investigational vaccine used in this clinical trial and designed&#xD;
      the trial protocol.For patients with advanced esophageal squamous carcinoma, gastric&#xD;
      adenocarcinoma, pancreatic adenocarcinoma and colorectal adenocarcinoma tumor who have&#xD;
      disease progression with first line chemotherapy. Single or multiple doses of personalized&#xD;
      mRNA tumor vaccine encoding neoantigen will be given to observe the safety and efficacy the&#xD;
      mRNA tumor vaccine.&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
      Determine the safety, tolerability and cytokinetics of the personalized mRNA tumor vaccine in&#xD;
      patients with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic&#xD;
      adenocarcinoma and colorectal adenocarcinoma.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Make a preliminary evaluation on the efficacy of personalized mRNA tumor vaccine in patients&#xD;
      with advanced esophageal squamous carcinoma, gastric adenocarcinoma, pancreatic&#xD;
      adenocarcinoma and colorectal adenocarcinoma with the following parameters:&#xD;
&#xD;
      Time of tumor progression (TTP);&#xD;
&#xD;
      Disease Control Rate (DCR);&#xD;
&#xD;
      Objective Remission Rate (ORR);&#xD;
&#xD;
      Overall Survival (OS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>24 weeks</time_frame>
    <description>During the trial conduction, especially within the 24 weeks of treatment phase when mRNA tumor Vaccine administered, all adverse events (including laboratory abnormality and clinical events) will be closely monitored, and all ≥ grade 3 adverse events per CTCAE (v 3.0) will be recorded, including but not limited to the toxicities potentially suspected to relate to injection procedures and/or mRNA Tumor Vaccine therapy as listed below:&#xD;
Fever&#xD;
Chills&#xD;
Nausea, vomiting and other gastrointestinal symptoms&#xD;
Fatigue&#xD;
Hypotension&#xD;
Respiratory distress&#xD;
Tumor lysis syndrome&#xD;
Neutropenia, thrombocytopenia&#xD;
Liver and kidney dysfunction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate of Personalized mRNA Tumor Vaccine</measure>
    <time_frame>1.5 years</time_frame>
    <description>Disease Control Rate (DCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival of Personalized mRNA Tumor Vaccine</measure>
    <time_frame>2 years</time_frame>
    <description>Progression-free Survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression of Personalized mRNA Tumor Vaccine</measure>
    <time_frame>2 years</time_frame>
    <description>Time to Tumor Progression (TTP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival of Personalized mRNA Tumor Vaccine</measure>
    <time_frame>3 years</time_frame>
    <description>Overall Survival (OS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Advanced Esophageal Squamous Carcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Colorectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Personalized mRNA Tumor Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Personalized mRNA Tumor Vaccine</intervention_name>
    <description>subcutaneous injection with personalized mRNA tumor vaccine at least four times</description>
    <arm_group_label>Personalized mRNA Tumor Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 - 75 with pathologically confirmed advanced Esophageal Squamous&#xD;
             Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal&#xD;
             Adenocarcinoma.&#xD;
&#xD;
          2. Patients with advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma,&#xD;
             Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma who have disease progression&#xD;
             with first line chemotherapy. (1) Failure of treatment is defined as disease&#xD;
             progression, recurrence or metastatic disease, or intolerable toxicities occurred&#xD;
             after treatment. (2) Each line of treatment during the period of disease progression&#xD;
             includes one or more chemotherapy drugs which are administered for not less than one&#xD;
             cycle or even longer. Neoadjuvant/adjuvant therapy can be applied at an earlier stage&#xD;
             of treatment. If patient has developed recurrence or metastatic disease within 24&#xD;
             weeks of neoadjuvant/adjuvant therapy, it is considered as one line of systemic&#xD;
             chemotherapy. (3) Therapies that can be performed at an earlier stage are chemotherapy&#xD;
             in conjunction with molecular targeted drugs.&#xD;
&#xD;
          3. Expected survival after first dose of study drug &gt; 24 weeks.&#xD;
&#xD;
          4. At least one measurable lesion (≥ 10 mm) for imaging assessment.&#xD;
&#xD;
          5. ECOG scores 0 - 1.&#xD;
&#xD;
          6. Fresh pathological tissue specimens can be obtained&#xD;
&#xD;
          7. White blood cells (WBCs) ≥ 2.5×10^9/L&#xD;
&#xD;
               -  Platelets (PLT) ≥ 100×10^9/L&#xD;
&#xD;
               -  Hemoglobin, Blood (Hb) ≥ 9.0 g/dL&#xD;
&#xD;
               -  MID ≥ 1.5×10^9/L&#xD;
&#xD;
               -  Lymphocyte (LY) ≥ 0.47×10^9/L&#xD;
&#xD;
               -  LY% ≥ 15%&#xD;
&#xD;
          8. Serum albumin (Alb) ≥ 30 g/L&#xD;
&#xD;
          9. Serum lipase (LPS) and serum amylase &lt; 1.5 ULN&#xD;
&#xD;
         10. Serum creatinine ≤ 1.5 ULN&#xD;
&#xD;
         11. Alanine aminotransferase (ALT) ≤ 2.5 ULN&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) ≤ 2.5 ULN&#xD;
&#xD;
               -  If osseous metastasis or liver metastasis is developed and alkaline phosphatase •&#xD;
                  (ALP) &gt; 2.5 ULN, ALT and AST &lt; 1.5 ULN.&#xD;
&#xD;
         12. Serum total bilirubin (TBIL) ≤ 1.5 ULN&#xD;
&#xD;
         13. Prothrombin Time (PT): International Normalized Ratio (INR) &lt; 1.7.&#xD;
&#xD;
               -  PT &lt; (ULN + 4) s&#xD;
&#xD;
        All test results should be within their normal ranges, and the patient is not receiving&#xD;
        continuous supportive care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with any of the following conditions are not eligible for the study.&#xD;
&#xD;
          1. Pregnant or lactating women.&#xD;
&#xD;
          2. HIV positive, HCV positive, HBV DNA copies ≥ 10^3.&#xD;
&#xD;
          3. Uncontrolled active infection.&#xD;
&#xD;
          4. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not&#xD;
             exclusionary.&#xD;
&#xD;
          5. Allergic to immunotherapies and related drugs.&#xD;
&#xD;
          6. Untreated brain metastases or having symptoms of brain metastases.&#xD;
&#xD;
          7. Metastases to the lung: central tumor or multiple metastases.&#xD;
&#xD;
          8. Patients with heart disease for which treatment is needed or with poorly controlled&#xD;
             hypertension.&#xD;
&#xD;
          9. Patients with unstable or active peptic ulcer or with alimentary tract hemorrhage.&#xD;
&#xD;
         10. Patients with previous organ transplantation or in preparation for organ&#xD;
             transplantation.&#xD;
&#xD;
         11. Patients have undertaken major surgeries or have been badly injured 4 weeks before the&#xD;
             study (blood collection), or will undertake major surgeries during the study.&#xD;
&#xD;
         12. The judgment of investigators that the patient is not able to or not willing to follow&#xD;
             the instructions of the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianbao Zhan, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Chanhai hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bin Wang, Dr.</last_name>
    <phone>+86 02131161448</phone>
    <email>qcwangb@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xianbao Zhan, Dr.</last_name>
    <phone>+86 02131161441</phone>
    <email>zhanxianbao@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Wang, Dr.</last_name>
      <phone>+86 01231161448</phone>
      <email>qcwangb@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xianbao Zhan, Dr.</last_name>
      <phone>+86 01231161441</phone>
      <email>Zhanxianbao@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xianbao Zhan, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bin Wang, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Bin Wang</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

